Solana captured 65% of all tokenized equities trading volume in one day, handling 85% more than all other blockchains combined. Tokenized equities are blockchain tokens tracking real stock prices, enabling 24/7 trading with fast settlement on decentralized exchanges (DEXs). In Q2 2026, Solana held 95-97% of global DEX tokenized equity volume, with trading reaching $5.8 billion, up 114% from the previous quarter. However, by late September 2026, Solana's market share dropped to about 35% as Robinhood Chain gained roughly 39%, signaling rising competition in the space.
Solana's tokenized equities trading volume is the subject here, presented with Pluang's market data for context. Of 50 major cryptocurrencies priced on Pluang, 35 rose and 14 fell today. Notable movers include EOS at Rp12.649 (+8.13%), ALGO at Rp2.240 (+5.41%) with a 42% Sell / 58% Buy split, and COTI at Rp242 (+3.80%) with 75% Sell / 25% Buy activity. This data is as of Oct 12, 2026 02:02 WIB.
Acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), was linked to an 18% lower risk of death, hospitalization, and disease progression compared to tafamidis in a large U.S. electronic health record study of 2,684 patients. The stud...
Stellantis revealed six concept cars from its iconic brands at an exclusive event before the Paris Motor Show, highlighting its FaSTLAne 2030 strategy focused on innovation, customer experience, and diverse mobility solutions. These concepts, includi...
Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade dysplasia APLs...
Donaldson Company is rated Buy due to its strong recurring replacement demand and diversified filtration portfolio that supports margin recovery and growth. The company's installed base and aftermarket sales provide resilience, while acquisitions lik...
Latigo Biotherapeutics is currently trading below its IPO value despite showing strong potential with its drug onzotrigine, which has demonstrated better efficacy in acute pain compared to Vertex's Journavx. The company benefits from leveraging Verte...
